SPRUCE BIOSCIENCES, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA, 94080
Phone
(415) 655-4168
Fiscal Year End
1231
EIN
812154263
Financial Overview
FY2025 FY
$4.91M
Revenue
$-50.83
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 9, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 9, 2026 | View on SEC |
| 3 Initial insider ownership report | March 9, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 9, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 24, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Developing Tralesinidase alfa enzyme replacement therapy (TA-ERT) for rare Sanfilippo Syndrome Type B (MPS IIIB).
- Aims for an accelerated approval pathway for TA-ERT to potentially speed up market entry.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.